HRP20031049A2 - Pyrrolopyrimidines as protein kinase inhibitors - Google Patents

Pyrrolopyrimidines as protein kinase inhibitors Download PDF

Info

Publication number
HRP20031049A2
HRP20031049A2 HR20031049A HRP20031049A HRP20031049A2 HR P20031049 A2 HRP20031049 A2 HR P20031049A2 HR 20031049 A HR20031049 A HR 20031049A HR P20031049 A HRP20031049 A HR P20031049A HR P20031049 A2 HRP20031049 A2 HR P20031049A2
Authority
HR
Croatia
Prior art keywords
ny1y2
alkyl
compound according
group
heteroaryl
Prior art date
Application number
HR20031049A
Other languages
English (en)
Croatian (hr)
Inventor
Tahir Nadeem Majid
Shelley Amendola
Stephanie Daniele Deprets
Chris Edlin
Brian Leslie Pedgrift
Frank Halley
Michael Edwards
Bernard Baudoin
Lain Mcfarlane Mclay
Davis John Aldous
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0115393.1A external-priority patent/GB0115393D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of HRP20031049A2 publication Critical patent/HRP20031049A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20031049A 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors HRP20031049A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds
US30167801P 2001-06-28 2001-06-28
PCT/GB2002/002835 WO2003000695A1 (fr) 2001-06-23 2002-06-21 Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases

Publications (1)

Publication Number Publication Date
HRP20031049A2 true HRP20031049A2 (en) 2004-06-30

Family

ID=26246238

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20031049A HRP20031049A2 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors

Country Status (11)

Country Link
US (1) US7259154B2 (fr)
KR (1) KR100875380B1 (fr)
AP (1) AP2003002929A0 (fr)
BG (1) BG108453A (fr)
CO (1) CO5540313A2 (fr)
CR (1) CR7193A (fr)
HR (1) HRP20031049A2 (fr)
IL (2) IL159506A0 (fr)
MA (1) MA27129A1 (fr)
MX (1) MXPA03011998A (fr)
NO (1) NO20035728L (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
WO2005012294A1 (fr) * 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. Composes 2,4-pyrimidinediamine a utiliser dans le traitement ou la prevention de maladies auto-immunes
JP2008508358A (ja) 2004-08-02 2008-03-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
FR2878849B1 (fr) * 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
JP2008543855A (ja) 2005-06-13 2008-12-04 ライジェル ファーマシューティカルズ， インコーポレイテッド 変形性骨疾患を処置するための方法および組成物
ATE352714T1 (de) * 2005-06-17 2007-02-15 Magneti Marelli Powertrain Spa Brennstoffeinspritzventil
EP1913000B1 (fr) 2005-07-29 2012-01-11 Pfizer Products Inc. Derives de pyrrolo[2,3-d]pyrimidine, leurs intermediaires et leur synthese
US20070219183A1 (en) * 2006-03-17 2007-09-20 Wyeth Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof
EP2265270A1 (fr) * 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. Inhibiteurs de 2-aminopyridine kinases
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
US8592448B2 (en) * 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP2569315A1 (fr) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
EP2706853B1 (fr) 2011-05-10 2017-06-14 Merck Sharp & Dohme Corp. Aminopyrimidines en tant qu'inhibiteurs de syk
CA2834062A1 (fr) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridylaminopyridines en tant qu'inhibiteurs de syk
EP2763975B1 (fr) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide
WO2013052391A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un phényl carboxamide
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
EP2863913B1 (fr) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Analogues d'imidazolyle en tant qu'inhibiteurs de syk
EP2863914B1 (fr) 2012-06-20 2018-10-03 Merck Sharp & Dohme Corp. Dérivés de pyrazolyle en tant qu'inhibiteurs de syk
EP2863915B1 (fr) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique (syk) diazines et triazines substituées
EP2863916B1 (fr) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Inhibiteurs à pyridine substituée de la tyrosine kinase de la rate (syk)
US9353066B2 (en) 2012-08-20 2016-05-31 Merck Sharp & Dohme Corp. Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
WO2014048065A1 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Dérivés triazolyle en tant qu'inhibiteurs de la syk

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1441497A (en) * 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
DE60037345T2 (de) * 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen

Also Published As

Publication number Publication date
US7259154B2 (en) 2007-08-21
NO20035728L (no) 2004-02-23
CR7193A (es) 2004-11-23
AP2003002929A0 (en) 2003-12-31
CO5540313A2 (es) 2005-07-29
US20040142947A1 (en) 2004-07-22
NO20035728D0 (no) 2003-12-19
BG108453A (bg) 2004-12-30
MXPA03011998A (es) 2005-07-01
HK1068134A1 (en) 2005-04-22
IL159506A0 (en) 2004-06-01
IL159506A (en) 2011-12-29
KR100875380B1 (ko) 2008-12-23
KR20040019317A (ko) 2004-03-05
MA27129A1 (fr) 2005-01-03

Similar Documents

Publication Publication Date Title
CA2451932C (fr) Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases
HRP20031049A2 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU2002314325A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU777717B2 (en) Azaindoles
KR100915289B1 (ko) 아자인돌
JP4871474B2 (ja) アザインドール
US9801878B2 (en) Quinoline derivatives as PDE10A enzyme inhibitors
NZ626279B2 (en) Quinoline derivatives as pde10a enzyme inhibitors

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: AVENTIS PHARMACEUTICALS INC., US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20110618

Year of fee payment: 10

OBST Application withdrawn